Compare Asana Inc. (ASAN) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Asana Inc. trades at $9.13 (market cap $2.13B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.4× Asana Inc.'s market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | BIO | |
|---|---|---|
Market Cap | $2.13B | $9.43B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $356.25 |
52-Week Low | $5.46 | $241.71 |
Enterprise Value | $1.96B | $9.18B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
